Oura Ring 5 Launch
The Oura Ring 5 isn't just a thinner ring — it's Oura laying track for an $11 billion IPO by transforming from a sleep tracker into a proactive health platform
TL;DR
- Oura launched the Ring 5 on 28 May — 40% smaller, 2.28mm thick, starting at $399 (shipping 4 June)
- New software: Health Radar with blood pressure signals, nighttime breathing monitoring, GLP-1 insights, live activity tracking, and telemedicine via Counsel Health
- Oura has sold 5.5M rings, has ~5M paying subscribers, $1B revenue in 2025, and is valued at $11B ahead of an IPO expected later this year
- The Ring 5 arrives just 18 months after the Ring 4 — the fastest cycle in Oura's history — as subscription-free rivals RingConn and Ultrahuman apply pressure
What Happened
On Thursday 28 May, Oura Health Oy unveiled the fifth generation of its smart ring. The Oura Ring 5 is 40% smaller than its predecessor, with thickness reduced from 3.5mm to approximately 2.28mm and width from 7.9mm to 6mm. It is constructed from non-allergenic titanium and, according to the company, "indistinguishable from a plain ring."
The hardware improvements are substantial: redesigned mechanical, electrical, optical, battery, and sensing architectures. More powerful LEDs and 12 stronger signal pathways promise improved accuracy across a wider range of finger sizes and skin tones. Battery life extends to 6–9 days, up from 5–8 on the Ring 4.
But the Ring 5 is a software story as much as a hardware one. Oura is launching "Health Radar," a background monitoring system with two foundational capabilities: Blood Pressure Signals (tracking cardiovascular patterns during sleep) and Nighttime Breathing (a 30-day rolling view of sleep-related breathing disturbances). The company has also partnered with Counsel Health to offer AI-enabled telemedicine consultations with licensed physicians directly through the Oura app — available in 43 US states at launch for an additional, undisclosed fee.
Other additions include GLP-1 insights for users on weight-loss medications, live activity tracking with real-time metrics on your phone, the ability to import medical records (diagnosed conditions, medications, lab results), and a new data-deletion tool that lets users wipe data within a specific time window.
The Ring 5 starts at $399 for Silver and Black finishes, $499 for Gold, Deep Rose, Brushed Silver, and Stealth. The required membership remains $5.99/month or $69.99/year. A portable charging case costs an additional $99. Preorders are open now, shipping 4 June.
What It Actually Means
This is not a routine product refresh. It is Oura preparing its narrative for public markets.
The company has sold 5.5 million rings across four generations and 150 countries. It has approximately 5 million paying subscribers. Revenue quadrupled over the past two years, reaching $1 billion in 2025. The company is valued at $11 billion and has confidentially filed for an IPO expected later this year.
The Ring 5's feature set tells you exactly what Oura wants institutional investors to see: a company transitioning from a wellness gadget maker into a healthcare platform. Blood pressure monitoring, sleep apnoea detection, GLP-1 tracking, telemedicine integration — these are not fitness features. They are clinical-adjacent capabilities that position Oura to compete for a slice of the $4.3 trillion US healthcare market, not just the wearables market.
The accelerated release cycle — 18 months from Ring 4 to Ring 5, versus the three-year gap between Rings 3 and 4 — is also telling. Subscription-free competitors RingConn (whose Gen 3 ships the day after the Ring 5 announcement) and Ultrahuman have been gaining ground. Oura is compressing its hardware cycle to maintain dominance while simultaneously building a software moat that hardware-only competitors cannot easily replicate.
Ben Wood, chief marketing officer at FDM CCS Insight, captured the dynamic: "Despite the quite significant subscription costs, it feels like you're getting value with its constant enhancements." Oura reports 80% member renewal after the first year and average wear time of 23.5 hours per day — engagement metrics that would make any SaaS company envious.
Hype Deconstruction
What this is not: A medical device. Oura is careful to use language like "Blood Pressure Signals" rather than "blood pressure monitoring." The ring detects patterns and trends — it does not replace a cuff. The Counsel Health partnership provides access to licensed physicians, but Oura itself is not providing medical care. These are important distinctions that will matter enormously when the FDA eventually takes a position on consumer wearables making health claims.
What this is not: A smartwatch replacement. The Ring 5 has no screen, no notifications, no apps. It is a passive data collector. For users who want real-time workout metrics on their wrist, an Apple Watch or Garmin remains the better tool. Oura's live activity tracking is phone-based, not ring-based.
What this is not: Cheap. At $399 plus $5.99/month, the total cost of ownership over two years is approximately $543 — more than an Apple Watch SE. The value proposition rests entirely on whether you believe continuous, passive health monitoring is worth that premium.
Stakeholder Landscape
Oura (the company): The Ring 5 is an IPO prospectus in product form. Every feature — blood pressure, sleep apnoea, GLP-1, telemedicine — maps to a healthcare TAM that is orders of magnitude larger than the smart ring market (4 million units shipped in 2025, per FDM CCS Insight).
Existing Oura users: The Ring 5 is a meaningful upgrade. The 40% size reduction addresses the most common complaint about smart rings. Software features roll back to Gen 3 and later, so existing users get Health Radar without upgrading hardware. The question is whether the hardware improvements justify $399 for Gen 3/4 owners.
Whoop: Oura's expansion into blood pressure and telemedicine puts it on a collision course with Whoop, which has 2.5 million subscribers and a $10 billion valuation. Both companies are now competing on health insights, not just fitness tracking.
RingConn, Ultrahuman, Samsung: The subscription-free competitors are the reason Oura accelerated its hardware cycle. Samsung's Galaxy Ring, launched in 2024, also avoids a subscription model. Oura's bet is that software and health insights justify the recurring fee. If consumers disagree, the pressure will intensify.
Healthcare incumbents: The Counsel Health partnership is a试探性 step toward Oura becoming a healthcare interface. If successful, it opens the door to insurance reimbursement, clinical trials, and integration with electronic health records — all of which would dramatically expand Oura's addressable market.
Cross-Layer Implications
Regulatory: Oura is walking a careful line with its health claims. "Blood Pressure Signals" is not "blood pressure measurement." But as the feature set grows more clinical, FDA attention is inevitable. The company's IPO timing may be influenced by a desire to establish its market position before the regulatory landscape crystallises.
Privacy: Oura is adding the ability to import medical records and delete data within specific time windows. These are table-stakes features for a company asking users to trust it with increasingly sensitive health data. The privacy-first framing in the launch materials is not accidental — it is pre-emptive reputational insurance ahead of the IPO.
Talent market: Oura now has 1,200+ employees across Helsinki, London, Los Angeles, San Diego, San Francisco, and Oulu. The company is competing for ML engineers, health data scientists, and regulatory specialists against both tech giants and healthcare companies. The IPO will be a recruiting tool as much as a liquidity event.
What This Means for You
If you own an Oura Ring Gen 3 or 4: The software features (Health Radar, live activity tracking, GLP-1 insights) roll back to your device. You do not need to upgrade for the health monitoring improvements. Upgrade if the 40% size reduction or improved battery life matters to you. Otherwise, wait.
If you are considering your first smart ring: The Ring 5 is the most capable smart ring on the market at launch. But the $399 + $5.99/month cost is significant. Compare against the RingConn Gen 3 (shipping now, no subscription) and Ultrahuman Ring Air ($349, no subscription) before committing. The question is whether Oura's software ecosystem justifies the recurring cost.
If you are a Whoop user: Oura's Health Radar and blood pressure signals are a direct challenge to Whoop's health monitoring positioning. If you value form factor (ring vs. band) and are willing to trade some training-specific metrics for a more discreet device, the Ring 5 warrants a look.
If you are an investor watching the wearables space: Oura's IPO will be the defining event for the smart ring category. The company's metrics — 5M subscribers, 80% retention, $1B revenue, 4x growth — are exceptional by any standard. The key risk is whether the subscription model holds against free competitors and whether regulatory scrutiny of health claims constrains growth.
Uncertainty Ledger
- Counsel Health pricing: Oura has not disclosed what the telemedicine consultations will cost. This is a significant variable for users considering the platform's healthcare value.
- Blood pressure accuracy: Oura has not published validation studies for the Blood Pressure Signals feature. Until independent testing confirms accuracy, treat the feature as indicative, not diagnostic.
- IPO timing: Oura has confidentially filed but has not announced a date. Market conditions in H2 2026 will determine whether the IPO happens on schedule.
- Regulatory risk: No FDA action is currently pending, but the trajectory toward clinical features makes regulatory engagement likely within 12–24 months.
Bottom Line
The Oura Ring 5 is the most important product the company has ever shipped — not because of the hardware, which is excellent, but because of what the software says about where Oura is heading. This is a company transitioning from "nice sleep tracker" to "health platform with 5 million paying subscribers" ahead of an $11 billion IPO. The Ring 5's blood pressure signals, sleep apnoea detection, GLP-1 tracking, and telemedicine integration are not features for today's users — they are proof points for tomorrow's investors. Whether the subscription model holds against free competitors is the single question that will determine whether Oura's IPO is a triumph or a reckoning.
Sources:
- The Guardian, "Oura launches Ring 5, world's smallest smart ring, as it heads towards IPO" (28 May 2026) — Tier 1
- TechCrunch, "Oura unveils its Ring 5 with a thinner, lighter design starting at $399" (28 May 2026) — Tier 1
- Forbes, "Oura Ring 5 Launch: Preorder Its Thinnest And Most Intelligent Smart Ring" (28 May 2026) — Tier 1
- Bloomberg, "Google's Fitbit Air Gives Whoop Some Serious Competition" (26 May 2026) — Tier 1
- Men's Health, "The Google Fitbit Air Is the Best New Fitness Tracker of 2026" (27 May 2026) — Tier 2
